Leading Life Sciences IP In-House: Strategy, Influence and Enterprise Execution

Leading an in-house life sciences IP function requires far more than knowing patent law. Senior IP counsel must navigate evolving legal doctrines, changing USPTO practices, regulatory and policy uncertainty, emerging technologies, competitive threats and litigation risk—while making decisions today about technologies and portfolios whose commercial consequences may not be known for years. The challenge is not simply identifying risk, but understanding which risks matter, anticipating where problems may emerge, and helping the enterprise make better long-term strategic decisions in an inherently uncertain environment.

This candid, off-the-record conversation will explore how senior in-house IP leaders actually do that job. Panelists will discuss how they work across R&D, clinical development, regulatory, business development, finance and executive leadership; translate complex patent issues into business consequences; influence decisions without owning every decision; set portfolio priorities and allocate resources; navigate pitfalls and competing pressures; and build organizational understanding of what IP can—and cannot—accomplish. The discussion will focus on the judgment, strategies and real-world leadership required to turn intellectual property from a legal function into an integral part of enterprise decision-making.